Biomatter Raises $18 Million for AI Enzyme Design

Biomatter raised $18 million in an oversubscribed Series A round led by Astanor, according to Tech.eu. Existing investors UVC Partners, Inventure and Metaplanet also participated.

The Lithuanian company combines computational models with laboratory testing to create enzymes for specific chemical reactions and industrial uses. Its proprietary dataset expands with each program, and its current design process takes weeks rather than months or years.

Biomatter has developed enzymes for customers including AstraZeneca, BASF, Sanofi and Tereos. It also worked with Thermo Fisher Scientific on an enzyme designed to improve stability in molecular biology and mRNA research applications.

The funding will support a 2,000 square meter enzyme design and testing facility in Vilnius, scheduled to open in 2027. Biomatter plans to bring more testing in house, reduce development timelines from weeks to days, expand its commercial team and presence in the United States, and continue building its computational platform and enzyme dataset.